Eyam Health Advances Cell Programming Platform for Infectious Diseases with Global Health Funded Large Animal Studies
Summary
Eyam Health is advancing its Gemini cell programming platform with new large-animal studies focused on infectious diseases, starting with a malaria monoclonal antibody program. The company aims to show that engineered cells can produce sustained therapeutic protein expression with lower cost and simpler logistics than conventional biologics. The studies will run sequentially at research centers in the United Kingdom and the United States, beginning with pigs and then moving to non-human primates. Eyam Health positions the platform as broadly applicable across infectious disease, oncology, chronic disease, and animal health. Results are expected in the first half of 2026, which could strengthen validation for the platform's commercial potential.